SGLT2 inhibitors × glycemic control

Observational studyInternational journal of clinical practice2017

Tolerability of canagliflozin in patients with type 2 diabetes mellitus fasting during Ramadan: Results of the Canagliflozin in Ramadan Tolerance Observational Study (CRATOS).

Mohamed Hassanein et al.PubMed ↗Full text ↗Publisher ↗

What the trial testedrandomised · 321 people · 2017

Randomised comparison

Probably lowered glycemic control

−73%−90% to −28%

Bigger than 8 in 10 for glycemic control

As reported

OR 0.273, 95% CI 0.10–0.72

One number in the abstract

the abstract, start to end

vs sulphonylurea (adjusted odds ratio: 0.273 [95% CI: 0.104, 0.719]).

← favours treatmentfavours comparator →
could be chance
Glycemic control
OR 0.2730.10–0.72
SGLT2 inhibitorsGlycemic control
1 / 3

22 papers cite it

2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
this paperpooled itcites it

The trial

Full record →Abstract, authors, funding and every citing paper · PMID 28851109